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1. Introduction 
In the last decade research on autoantibodies in neurological diseases of the central nervous 
system (CNS) has been very successful. An increasing number of autoantibodies and their 
target antigens have been detected, supporting stratification of patients and enabling specific 
treatment. The detection of autoantibodies depends on the assay used, as antibody binding 
requires the native conformation of the antigen. Although cumulative data is suggesting an 
important role of B cells and antibodies in Multiple Sclerosis (MS), numerous studies failed to 
identify specific biomarkers for MS (Figure 1). Even though several clinical, immunological 
and radiological studies tried to discover risk factors for disease progression, it remains an 
open issue to predict the individual disease course. However, recently autoantibodies have 
been discovered in some rare CNS demyelinating disease closely resembling MS (Table 1). 
Particularly Neuromyelitis Optica (NMO) gained enormous interest due to the discovery of 
autoantibodies targeting the water channel protein aquaporin-4 (AQP4) (Lennon et al., 2004; 
Lennon et al., 2005), which is expressed on astrocytic endfeet at the blood brain barrier 
(Nicchia et al., 2004) (Figure 1). This inflammatory demyelinating disease represents itself with 
optic neuritis and longitudinally extensive transverse myelitis (Wingerchuk et al., 1999) and 
was long considered as a severe variant of MS. Due to the detection and validation of this 
highly sensitive and specific biomarker, NMO is now regarded as a separate disease entity to 
MS. Consequently, the anti-AQP4 antibody serostatus was included into the diagnostic criteria 
of NMO (Jarius et al., 2007; Wingerchuk et al., 2007). Compared to MS, patients with NMO 
have a worse prognosis and require different treatment strategies according to the dominant 
humoral immunopathogenesis. With the advent of anti-AQP4 antibodies as biomarkers in 
NMO spectrum disorders (NMOSD), different NMO antibody assays have been developed, 
whereby cell based assays using the M23 isoform of AQP4 yield highest sensitivity (Takahashi 
et al., 2007; Waters & Vincent, 2008; Mader et al., 2010). Despite the high percentage of anti-
AQP4 IgG positive NMO patients, various studies described a lack of these autoantibodies in a 
cohort of NMO patients, which we will critically discuss in this chapter. It remains an open 
question whether these patients form their own subgroup of NMO patients or if the antibodies 
are not detected due to a sensitivity problem of the applied assays. Moreover, we will address 
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the relevance of autoantibodies for the classification of neurological diseases and discuss novel 
findings of a potential involvement of T cells in NMO. 
 
 MS NMO ADEM 
Prevalence 100 / 100,000 1 / 100,000 1 / 100,000 
Female : Male ratio 3 : 1 9 : 1 1 : 2 
Disease onset 20-30 years 40 years Childhood 
Disease course 
Relapsing-remitting 
progressive 
Relapsing-
remitting 
Monophasic, 
recurrent 
Clinical symptoms Variable 
Optic neuritis, 
myelitis 
Encephalopathy, 
multifocal 
Brain MRI 
Multiple white 
matter lesions 
Normal or 
atypical for MS 
Multifocal large 
bilateral lesions 
Spinal MRI 
Short-segment (<3) 
lesions 
Long-segment 
(>3) lesions 
Confluent 
CSF IgG OCB + Frequent (>90%) Rarely Rarely 
Relapse treatment Intravenous high-dose methylprednisolone, plasma exchange 
Interval treatment 
IFN-ß, GA, Tysabri, 
Fingolimod, AZT 
AZT + steroids, 
Rituximab 
None 
Environmental 
triggers 
Infections, Vitamin-
D, smoking 
Unknown 
Infection, 
vaccination 
Diagnostic marker  AQP4-IgG MOG-IgG 
Table 1. Important human inflammatory demyelinating diseases. IFN-ß = interferon-beta, 
GA = glatiramer acetate, AZT = azathioprine, MRI = Magnetic resonance imaging, OCB = 
oligoclonal bands. 
Controversial results regarding the detection of autoantibodies to myelin oligodendrocyte 
glycoprotein (MOG) in patients with MS have confused researchers for several years. Latest 
findings showed increased anti-MOG antibody titers in a subgroup of patients with acute 
disseminated encephalomyelitis (ADEM) and childhood MS, but not in adult MS (O'Connor 
et al., 2007; Brilot et al., 2009; Di Pauli et al., 2011; Lalive et al., 2011). The target antigen 
MOG is expressed on the outer surface of the myelin sheath (Figure 1) and can only be 
detected using cell based assays expressing MOG on their surface. Early stratification from 
MS is of great relevance as ADEM is usually a self-limiting disease. However, due to the 
high number of anti-MOG antibody negative ADEM patients, early diagnosis remains 
challenging in some cases.  
An early detection of autoantibodies to the NMDA (N-methyl D-aspartate) receptor is 
crucial in anti-NMDA-receptor encephalitis, an acute form of encephalitis, which can have a 
neuropsychiatric presentation, seizures, dyskinesias or autonomic instability (Dalmau et al., 
2007). This disease is potentially reversible if it is recognized and treated as early as possible. 
In paraneoplastic courses a removal of the tumour is mandatory, but NMDA-receptor 
encephalitis can also be non-paraneoplastic and affect both genders. Detection of antibodies 
to the neuronal cell surface antigen NMDA-receptor (NMDA-R, Figure 1) in serum of 
patients supported a better understanding of the disease pathomechanism. In this chapter 
we will report on the latest findings of autoantibodies in CNS diseases, primarily focusing 
on anti-AQP4 antibodies in NMO, the relevance of anti-MOG antibodies in ADEM and MS 
and antibodies to NMDA-R in anti-NMDA-receptor encephalitis. 
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Fig. 1. Discovery of autoantibodies and their target antigens in different CNS diseases. 
2. B cells and antibodies in MS 
MS is the most frequent inflammatory demyelinating disease in young adults with a high 
risk of future disability and a heterogeneous clinical presentation (Noseworthy et al., 2000). 
Approximately 2.5 million people are affected, experiencing different disease courses. In the 
majority of patients (85-90%), the disease follows a relapsing–remitting course (RR-MS), 
characterized by acute relapses and subsequent complete or incomplete remission (Sospedra 
& Martin, 2005). RR-MS patients often convert into a secondary progressive disease course 
(SP-MS) (Sospedra & Martin, 2005). In contrast, a minority of patients suffer from the 
primary-progressive disease course (PP-MS, 10-15%) with a steady disease progression 
(Sospedra & Martin, 2005). Although the etiology of MS remains unresolved, currently it is 
believed that components of the myelin sheath are attacked by autoreactive T cells involving 
the cellular and humoral immune system (Sospedra & Martin, 2005). This infiltration of 
inflammatory cells within the CNS results in inflammation, thus leading to demyelination of 
the myelin sheaths, which cover the nerve fibers. Brain MRI shows typically multiple white 
matter lesions, with frequent development of new lesions. In the last decade, increasing 
research is focusing on the relevance of B cells and antibodies in MS, investigating their role 
and contribution in the initiation and propagation of inflammatory demyelinating processes 
at different disease stages (Figure 2). 
In at least a subset of MS patients, pathogenic antibodies are believed to cause 
demyelination and axonal loss. This resulted in an extensive research in order to identify the 
still unknown target antigen. The detection of intrathecal IgG synthesis and the occurrence 
of oligoclonal bands (OCB) in the CSF of more than 90% of MS patients supports the impact 
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Fig. 2. Increasing evidence suggests an important role of B cells in MS. Currently, research is 
focusing on their relevance for antigen presentation and T cell activation, production of 
cytokines and antibodies. 
of humoral immune responses in the pathogenesis of MS (Kabat et al., 1948). This seminal 
finding in 1948 is still an immunological hallmark for the disease, with the incorporation of 
OCB as diagnostic marker for MS (Freedman et al., 2005). However, OCBs are not unique for 
MS, as they are commonly detected in infectious diseases (Freedman et al., 2005), 
underlining the urgent need for specific biomarkers. A central role for B cells in the disease  
pathology can be attributed to studies showing a deposition of antibodies and complement 
in acute MS lesions (Lucchinetti et al., 2000) and histopathological studies confirming an 
antibody mediated demyelination (Lucchinetti et al., 1996; Storch et al., 1998) . Furthermore, 
clonally expanded B lymphocytes were discovered in chronic MS plaques and in the CSF of 
MS patients (Qin et al., 1998; Colombo et al., 2000; Owens et al., 2003). Latest studies 
highlight the role of B cells in the disease pathogenesis, as B cell depletion with the chimeric 
anti-CD20 monoclonal antibody rituximab had an impact on reduced inflammatory brain 
lesions in MS patients (Hauser et al., 2008). Nevertheless, there is a lack of unique 
biomarkers for MS, although numerous studies have focused on the presence of 
autoantibodies against potential antigens of the myelin sheath (Figure 3) and infectious 
agents in serum and CSF of patients (Reindl et al., 2006). 
2.1 Anti-MOG antibodies and MS 
One promising potential candidate as target antigen for MS is the myelin oligodendrocyte 
glycoprotein (MOG), a CNS specific antigen, which has been studied for several decades 
now. This transmembrane protein is localized on the outer membrane of myelin sheaths and 
oligodendrocytes (Figure 3) (Brunner et al., 1989).  
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Fig. 3. MOG is expressed on the outer myelin surface.  
Anti-MOG antibodies are pathogenic in vitro (Kerlero de Rosbo et al., 1990) and in vivo, as 
immunization with the MOG protein induces severe experimental autoimmune 
encephalomyelitis (EAE), which is commonly used as animal model for MS (Linington et al., 
1993; Amor et al., 1994; Adelmann et al., 1995; Genain et al., 1995; Weissert et al., 1998). 
Immunization of MOG in adjuvant or adoptive transfer of activated myelin-specific T cells 
results in a MS like pathology in EAE (Goverman, 2009). Anti-MOG antibodies are proposed 
to augment disease severity by enhancing T cell and macrophage initiated demyelination 
(Zhou et al., 2006). In addition to their relevance in animal models, anti-MOG 
autoantibodies were discovered in active MS brain lesions (Genain et al., 1999), yet their 
presence in the CSF and serum of MS patients remains controversial and there are ongoing 
studies trying to solve these conflicting outcomes (Reindl et al., 2006). Following a 
publication of our group showing that increased serum anti-MOG and anti-MBP IgM 
antibodies in patients with clinically isolated syndrome (CIS), the most common first 
manifestation of MS, predict early conversion to clinically definite MS (Berger et al., 2003), 
numerous other studies were performed with correlations ranging from highly significant 
(Greeve et al., 2007; Tomassini et al., 2007), significant in a subanalysis (Rauer et al., 2006; 
Kuhle et al., 2007a) or not significant at all (Rauer et al., 2006; Kuhle et al., 2007a; Kuhle et al., 
2007b). Possible explanations for this controversy could be linked to discrepancies in 
antibody assays, study designs and the investigated populations (Bar-Or & Antel, 2008). 
Former studies used mainly Western Blot, ELISA and liquid phase assays for the analysis of 
anti-MOG antibodies, which detect primarily linear epitopes of the MOG protein or partially 
refolded MOG. These assays were performed using bacterially expressed fragments of the 
MOG protein (MOG1-125). However, binding of pathogenic serum anti-MOG antibodies 
might require native MOG with its posttranslational modifications. As the commonly used 
Western Blot and ELISA techniques led to inconsistent results, new assays were developed 
detecting conformational epitopes of MOG. Therefore, cell-based assays were used 
reflecting the correct formation and glycosylation of native MOG in the human CNS. 
Increased levels of autoantibodies to native MOG were observed in MS patients during 
relapse and in SP-MS, compared to patients in remission and controls when performing an 
ELISA coated with native MOG expressed by eukaryotic cells (Gaertner et al., 2004). A 
higher frequency of antibodies to native MOG was detected using cell lines expressing full 
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length human MOG (Lalive et al., 2006; Zhou et al., 2006). Although both studies used cell 
based assays, the frequency of anti-MOG antibodies within the MS disease course varied in 
both studies. Lalive and colleges reported increased titers of serum anti-MOG antibodies in 
patients with CIS, RR-MS and to a smaller extend in SP-MS, but not in healthy controls or 
PP-MS patients (Lalive et al., 2006). This is in contrast to a study of Zhou, observing the 
highest frequency of pathogenic autoantibodies to MOG in PP-MS patients using a flow 
cytometry-based assay. Moreover, Zhou and colleges demonstrated a pathogenic role of 
human anti-MOG antibodies in vitro and in vivo following injection into susceptible rat 
models (Zhou et al., 2006). Summarizing, the relevance of anti-MOG antibodies in MS 
remains controversial. Latest findings using a novel tetramer radioimmunoassay indicated 
the presence of conformation dependent anti-MOG antibodies is a subset of pediatric 
patients with acute disseminated encephalomyelitis (ADEM) and pediatric MS, but rarely in 
adult onset MS (O'Connor et al., 2007). 
2.2 High titer anti-MOG antibodies in ADEM patients 
ADEM is a rarely occurring inflammatory demyelinating disease of the CNS, brain and 
spinal cord, with an unknown relationship to MS. In patients with ADEM, acute or subacute 
multifocal large bilateral white matter lesions, frequently involving deep grey matter 
regions are accompanied by the occurrence of encephalopathy (Mikaeloff et al., 2004; Krupp 
et al., 2007). Although guidelines have been published to support the diagnosis of ADEM, 
diagnosis can be complicated, as exact diagnostic criteria are missing. Thus, the incidence 
remains to be investigated. Some publications suggest a prevalence rate of 0.8 per 100,000 
affected patients per year (Leake et al., 2004). Whereas some reports describe no gender 
predisposition (Dale et al., 2000; Leake et al., 2004), most studies indicate a slight male 
preponderance in ADEM patients (Pavone et al., 2010). Although the majority of patients 
with ADEM follow a monophasic disease course, recently recurrent or multiphasic forms 
have been described with a lower incidence rate (Rust, 2000; Hynson et al., 2001). ADEM 
commonly occurs after a vaccination (post-vaccination encephalomyelitis) or infection (post-
infection encephalomyelitis). In a study of Tenembaum, analyzing 84 pediatric ADEM 
patients, neurological disturbances occurred in 74% of patients following vaccination or 
infection (Tenembaum et al., 2002). ADEM is more often described in pediatric patients and 
juveniles (Leake et al., 2004), however, adult cases have also been reported (Schwarz et al., 
2001). In contrast to the persistent disease course of MS, 57-89% of ADEM patients show 
complete recovery (Dale et al., 2000; Tenembaum et al., 2002). Furthermore, acute treatment 
with corticosteroids, immunoglobulins and plasma exchange often results in amelioration of 
ADEM patients, for which reason a biomarker is of high relevance in order to stratify MS 
and ADEM. Primarily at disease onset, ADEM can be misdiagnosed as CIS (Mikaeloff et al., 
2007). The International Consensus criteria of 2007 can serve as guidelines for diagnosing 
CIS or ADEM (Krupp et al., 2007). Recently, a retrospective study was published analyzing 
the role of MRI in 28 children with MS and 20 ADEM patients (Callen et al., 2009). Herby, 
Callen et al. demonstrated a lower age of onset for ADEM patients compared to pediatric 
MS. This study invented new MRI diagnostic criteria to help differentiating RR-MS from 
monophasic ADEM at disease onset, yielding a high sensitivity (81%) and specificity (95%) 
(Callen et al., 2009). Contrary to MS which is typically associated with the development of 
new lesions, ADEM lesions usually resolve or show residual findings (Kesselring et al., 
1990). Therefore, a follow-up MRI within a time period not shorter than 6 months is helpful 
for diagnosis (Kesselring et al., 1990). Analysis of CSF can support the diagnosis, as OCB are 
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infrequently detected in patients with ADEM (Stuve et al., 2005; Franciotta et al., 2008), yet a 
biomarker with high specificity is warranted. Recently, ADEM has attracted rising interest 
due to the discovery of anti-MOG autoantibodies in a subset of patients (O'Connor et al., 
2007). In their study, O`Connor and colleges used a tetramer radioimmunoassay and 
detected serum antibodies directed to folded MOG tetramer in patients with ADEM in 
higher concentrations compared to adult MS cases (O'Connor et al., 2007). This observation 
was confirmed by several other publications (Brilot et al., 2009; Di Pauli et al., 2011; Lalive et 
al., 2011). Serum antibodies to native MOG were most commonly reported in pediatric 
ADEM patients. Although, a recent study of our group detected native MOG autoantibodies 
predominantly in children, we additionally observed few adult anti-MOG antibody positive 
ADEM cases (Di Pauli et al., 2011). Furthermore, we performed longitudinal analysis of anti-
MOG antibodies and showed that a decrease of anti-MOG antibodies in ADEM patients was 
associated with a more favorable clinical outcome (Di Pauli et al., 2011). Anti-MOG IgG was 
detected in the CSF of high titer seropositive patients, suggesting a rather peripheral 
production of antibodies directed to MOG (Di Pauli et al., 2011). Even though anti-MOG 
antibodies might support the diagnosis of ADEM in a subset of patients, additional 
biomarkers are warranted for the remaining large proportion of anti-MOG antibody 
negative ADEM patients. Furthermore, the relevance of ADEM specific high titer anti-MOG 
antibodies for disease pathogenesis should be further analyzed.  
3. Anti-AQP4 autoantibodies in NMO 
NMO is a rare devastating inflammatory demyelinating disease of the CNS. In former times 
it was believed to be a severe variant of MS, the most common neurological disease in 
young adults. In contrast to MS, it has several unique features (Table 1). NMO is 
characterized by the occurrence of optic neuritis (ON) and longitudinally extensive 
transverse myelitis (LETM) extending over three or more vertebral segments (Wingerchuk 
et al., 1999; Cree, 2008), which can lead to blindness and paraplegia within several years of 
disease onset (Wingerchuk et al., 1999; Wingerchuk & Weinshenker, 2003). Furthermore, 
NMO commonly follows a more aggressive disease course compared to MS and has a high 
rate of morbidity and mortality in patients who receive no special treatment (Wingerchuk & 
Weinshenker, 2003). Especially at disease onset, the diagnosis can be complicated by a long 
lasting time interval between the occurrence of LETM and ON. Whereas OCB are detected 
in the CSF of approximately 90% of MS patients (Kabat et al., 1948), they are rarely or 
transiently present in patients with NMO (0-37%) (Wingerchuk et al., 1999). In addition, the 
diagnosis of NMO can be supported by the detection of CSF pleocytosis (>50 x106 white 
blood cell count /L) during acute relapses (Zaffaroni, 2004), which is not indicative for MS. 
Originally, NMO was described in 1894 by Eugene Devic and Gault as acute monophasic 
disorder with simultaneous occurrence of ON and LETM (Minagar et al., 2002). Due to a 
tremendous increase in the scientific interest for this disease, many aspects from the original 
view of NMO have changed. Nowadays, NMO is characterized as a mainly relapsing 
disease (80-90%), with a minority of patients suffering from a monophasic course 
(Wingerchuk et al., 2007; Sellner et al., 2010). Whereas NMO was initially described by a lack 
of brain MRI lesions, MS-atypical brain lesions are found in some NMO patients primarily 
at sites of high AQP4 expression (Pittock et al., 2006). However, a negative brain MRI at 
disease onset is not indicative for MS (Jarius et al., 2008b). The explosive rise in the field of 
NMO research was mainly due to the discovery of NMO-IgG autoantibodies, mostly IgG1, 
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in serum of NMO patients, but not in classical MS or any other controls (Lennon et al., 2004). 
This marvelous achievement is attributed to Vanda Lennon and her group, discovering one 
year later the AQP4 water channel protein as target antigen of NMO autoantibodies 
(Lennon et al., 2004; Lennon et al., 2005). This transmembrane channel protein constitutes an 
essential part of the blood brain barrier due to its localization in pericapillary endfeet 
processes and ependymal cells facing the ventricles (Figure 1) (Nielsen et al., 1997; Rash et 
al., 1998; Nicchia et al., 2004). The discovery and validation of this highly specific biomarker 
resulted in the incorporation of the anti-AQP4 antibody serostatus in the diagnostic criteria 
of NMO, achieving high sensitivity (99%) and specificity (90%) (Jarius et al., 2007; 
Wingerchuk et al., 2007) (Table 2).  
 
Absolute criteria Supportive criteria 
1. Optic neuritis 1. Brain MRI atypical for MS 
2. Acute myelitis 
2. Spinal cord MRI with contiguous T2-
weighted signal abnormality extending 
over 3 or more vertebral segments 
 3. Anti-AQP4 IgG seropositive status 
Table 2. Revised diagnostic criteria of NMO (Wingerchuk et al., 2007). Definite NMO 
requires fulfillment of both absolute criteria and of two of the 3 supportive criteria. 
Since the discovery of anti-AQP4 IgG, NMO is considered as a separate disease entity with 
an unknown relationship to MS. Thus, the detection of anti-AQP4 antibodies facilitates an 
early stratification of NMO and MS, which is highly important due to the different 
treatment recommendations. Compared to MS, NMO patients have a worse prognosis and 
require distinct treatment strategies due to the dominant humoral immunopathogenesis. 
Whereas immunomodulatory therapies are frequently applied for treating MS, 
immunosuppressive treatment is more promising for NMO (Sellner et al., 2010). Interferon 
beta (IFN-ß) and glatiramer acetate (GA) were shown to be beneficial in MS, whereas in 
NMO patients these drugs have an ineffective or even deleterious effect (Papeix et al., 2007; 
Warabi et al., 2007). Acute attacks are commonly treated by a combination of corticosteroids 
and immunosuppressive agents. Plasma exchange or treatment with rituximab can prevent 
NMO attacks in patients not responding to corticosteroids (Cree et al., 2005; Watanabe et al., 
2007; Jacob et al., 2008; Bonnan et al., 2009).  
3.1 NMO epidemiology and genetic factors  
Limited reports are published concerning the epidemiology of NMO in different ethnic 
groups (Kira, 2006; Cabrera-Gomez et al., 2009; Collongues et al., 2010), and thus the 
incidence and prevalence of NMO remains unknown. Some studies indicate a prevalence of 
one per 100,000 patients (Cabre, 2009; Cabrera-Gomez et al., 2009), however these studies 
use different antibody assays. Presumably, a proportion of patients remains to be falsely 
diagnosed as severe variant of MS. Available data suggest a higher incidence in non-
Caucasian countries, especially in Latin American, East Asian and African populations 
compared to Northern European countries (Osuntokun, 1971; Kira et al., 1996; Papais-
Alvarenga et al., 2002). NMO occurs up to nine times more often in women than in men 
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(Wingerchuk et al., 2007), with a median age of onset at around 40 years (Wingerchuk et al., 
2007). Female patients were far more likely to develop the recurrent disease course 
(Wingerchuk, 2009), yet the gender had no impact on the type or severity of initial attacks, 
recovery from initial attacks, relapse frequency or disease related mortality (Wingerchuk, 
2009). A genetic predisposition for NMO was recently indicated by some case reports, which 
are mainly based on studies of sibling pairs and a parent-child case (Mirsattari et al., 2001; 
Rivera & Cabrera, 2001; Braley & Mikol, 2007; Cabrera-Gomez et al., 2009). Furthermore, 12 
pedigrees of NMO patients with a total number of 25 patients were recently analyzed by 
Mattiello and his group, resulting in 3% familial NMO cases in patients with clinical definite 
NMO (Matiello et al., 2010). This number might be larger when also including patients with 
high risk NMO, as the disease can have a heterogeneous presentation (Pellkofer et al., 2009).  
3.2 Anti-AQP4 antibodies as biomarkers for NMO-spectrum disorders 
With the advent of anti-AQP4 antibodies as biomarkers in NMOSD (Lennon et al., 2004; 
Lennon et al., 2005), various NMO antibody assays have been developed (Lennon et al., 
2004; Lennon et al., 2005; Paul et al., 2007; Takahashi et al., 2007; Marignier et al., 2008; 
Waters & Vincent, 2008; Mader et al., 2010). The choice of assay is crucial for the 
identification of NMO IgG autoantibodies in serum and CSF samples of patients. The first 
assay describing the presence of NMO autoantibodies applied an indirect 
immunofluorescence (IF) assay with a composite substrate of adult mouse cerebellum 
sections (Lennon et al., 2004). This assay was described by the group of Vanda Lennon, 
achieving 58-73% sensitivity and 91-100% specificity for NMO. One year later the AQP4 
water channel protein was detected as target antigen using human embryonic kidney cells 
(HEK) transfected with human AQP4 (Lennon et al., 2005). The establishment of cell based 
assays using transfected HEK cells resulted in an even higher sensitivity than the tissue 
based IF assays, resembling most likely the native conformation of the AQP4 protein 
(Takahashi et al., 2006; Takahashi et al., 2007; Mader et al., 2010). For this purpose, the cells 
were transfected with the AQP4 protein fused to a green fluorescence protein. After 
addition of the NMO samples, the bound anti-AQP4 antibodies were detected using a 
secondary antibody. Positive samples were visualized by a co-staining of NMO IgG (red) 
with the AQP4 expressing cells (green), as demonstrated in Figure 4 (Takahashi et al., 2006; 
Mader et al., 2010). 
 
 
Fig. 4. Detection of an anti-AQP4 IgG seropositive patient with our live cell staining IF assay 
(Mader et al., 2010). Human anti-AQP4 IgG (red, B) in patient`s serum bind to the AQP4-
EmGFP transfected cells (green, A), resulting in co-localisation (merge, C). 
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This assay has the advantage of determining titer values of NMO antibody positive patients 
by serial dilutions of serum samples until loss of signal. However, the relevance of these 
titer levels remains controversial. As the AQP4 transmembrane protein is either expressed 
as full length M1 or as 23 amino acid shorter M23 AQP4 (Figure 5) (Neely et al., 1999; 
Furman et al., 2003), many studies lack the information regarding the usage of the AQP4 
isoform. Recently, our group demonstrated that anti-AQP4 antibodies primarily target the 
shorter M23 AQP4 isoform, whereas antibodies to full length AQP4 were developed with 
increasing disease duration and number of relapses (Mader et al., 2010). For this purpose we 
used a live cell staining IF assay with transiently transfected HEK cells, resulting in 97% 
sensitivity for NMO and 65% for high risk NMO, with a specificity of 100% compared to 
controls (Mader et al., 2010). Our assay showed different staining patterns for M1 and M23 
AQP4 transfected cells (Mader et al., 2010). In contrast to M1 AQP4, M23 AQP4 forms 
orthogonal arrays of particles (Figure 5 B), which are currently believed to be potential 
targets of antibody binding (Nicchia et al., 2009). Consequently the NMO IF assay yields 
highest sensitivity when using cell-based assay with M23 AQP4 transfected cells.  
 
 
Fig. 5. Structure (A) and expression pattern (B) of the M1 and M23 AQP4 isoforms.  
3.3 “Anti-AQP4 seronegative NMO“  
The terminus “anti-AQP4 seronegative NMO” should be handled with care, as several 
factors contribute to the antibody serostatus. A broad range of antibody assays is available 
resulting in diverse sensitivity and specificity. Consequently, the percentage of seronegative 
NMO patients is fluctuating depending on the methodology approach. Cell-based assays 
using the M1 or M23 AQP4 isoform have an impact on the number of seronegative NMO 
patients. A negative antibody status might be credited to an administered therapy prior to 
testing. A depletion of antibodies below a detectable threshold could explain a negative 
serostatus. Although, anti-AQP4 antibodies have been detected up to ten years before 
disease onset (Nishiyama et al., 2009), we have analyzed a small number of patients who 
were initially negative for NMO IgG and turned out to be low titer positive in longitudinal 
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samples (unpublished results). For this reasons, one has to be careful when dealing with the 
term “seronegative NMO”. Moreover, seronegative NMO might resemble another disease 
course with overlapping clinical features. Particularly, pediatric NMO can present itself with 
diverse clinical features, and therefore stratification from MS can be difficult especially at 
disease onset (Lotze et al., 2008). The diagnosis might further be supported by analyzing 
CSF of patients. Recently, glial fibrillar acidic protein (GFAP), a marker of astrocytic 
damage, was shown to be significantly elevated in the CSF of NMO patients compared to 
classical MS (Misu et al., 2009), however this increase was primarily detectable during 
relapse (Misu et al., 2009). In conclusion, the anti-AQP4 antibody serostatus should be 
repeatedly analyzed in NMOSD using highly sensitive and specific cell based assays. The 
absence of anti-AQP4 antibodies over a long time interval indicates a different disease 
pathomechanism compared to patients with “AQP4 autoimmune channelopathy”. 
Consequently ongoing research should focus on the discovery of new biomarkers for anti-
AQP4 seronegative patients with NMO. 
3.4 NMO-spectrum disorders 
Apart from clinical definite NMO, anti-AQP4 IgG antibodies are frequently detected in 
limited forms of NMO (Wingerchuk et al., 2007). These patients do not fulfill the complete 
diagnostic criteria of NMO, but harbor a high risk of developing clinically definite NMO 
(Pittock et al., 2008; Mader et al., 2010). Therefore, NMO and high risk NMO patients 
represent the group of NMOSD, suffering either from monophasic bilateral or recurrent ON 
or LETM (idiopathic, isolated or recurrent) (Wingerchuk et al., 2007). Currently NMO IgG 
positive patients with recurrent ON were shown to have a poor visual outcome and were 
more likely to develop NMO in a longitudinal study (Matiello et al., 2008). Anti-AQP4 IgG 
seropositivity predicted a relapse in patients with a first episode of LETM event extending 
over three or more vertebral segments (Weinshenker et al., 2006). In 50% of these anti-AQP4 
IgG seropositive LETM patients either ON occurred or LETM relapsed within half a year 
(Weinshenker et al., 2006). Furthermore, anti-AQP4 antibodies have been frequently 
detected in systemic autoimmune disorders presenting themselves with ON or LETM, such 
as neuropsychiatric systemic lupus erythematosus (SLE), Sjogren's syndrome, myasthenia 
gravis or thyroiditis (Wingerchuk et al., 2007). However, anti-AQP4 antibodies were 
detected exclusively in systemic autoimmune disorders in combination with NMO or High 
Risk NMO symptoms. The presence of anti-AQP4 antibodies could indicate a coexistence of 
systemic autoimmune disorders with NMO (Pittock et al., 2008; Wandinger et al., 2010), 
rather than an epiphenomenon (Pittock et al., 2008; Wandinger et al., 2010), yet their 
relationship remains unidentified. 
3.5 Serum titer levels of anti-AQP4 IgG antibodies  
The role of serum anti-AQP4 antibody titers remains controversially described. Takahashi 
and his group showed an involvement of AQP4-IgG antibody titers in disease 
pathogenesis, detecting a correlation with spinal cord lesion length (Takahashi et al., 
2006). This study analyzed 148 serum samples of Japanese patients including 35 patients 
with NMO-spectrum disorders and demonstrated elevated AQP4-IgG titer levels in 
patients with permanent complete blindness, LETM and extensive or large cerebral 
lesions (Takahashi et al., 2006). In addition, a longitudinal study of eight NMO-IgG 
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positive patients reported a correlation of serum anti-AQP4 Ig with clinical disease 
activity (Jarius et al., 2008a), demonstrating a threefold intra-individual increase of AQP4 
IgG titers during relapse, which was not accompanied by other serum antibodies 
(Takahashi et al., 2006). Some papers suggest an effect of treatment on antibody titers, 
showing a reduction of NMO antibody titer levels after immunosuppressive treatment 
(Takahashi et al., 2006; Jarius et al., 2008a). Recently, an increase of anti-AQP4 antibody 
titers was described in one NMO patient following immunomodulatory treatment with 
IFN-ß (Palace et al., 2010). Applying conventional immunosuppressive therapy, the 
antibody titers decreased again in this patient (Palace et al., 2010), high lightening the 
importance of an early stratification of MS and NMO.  
3.6 AQP4-IgM antibodies 
Although, IgM antibodies binding to AQP4 were described at NMO lesion sites (Lucchinetti 
et al., 2002; Roemer et al., 2007), their role in the disease course remains unresolved. Most 
studies investigating autoantibodies against AQP4 refer to IgG antibodies. We addressed 
this issue in a recent study analyzing IgG and IgM antibodies directed to M23 AQP4 in 
serum of patients with NMO-spectrum disorders and in other disease groups using a live 
cell staining IF assay (Mader et al., 2010). In contrast to NMO IgG, which was exclusively 
detected in 97% of NMO patients and 65% of suspected NMO, M23 IgM antibodies were 
elevated in NMO (27%) and high risk NMO (12%). However, IgM antibodies to M23 AQP4 
were additionally present in NMO IgG seronegative patients with isolated myelitis, MS (4%) 
and OND (4%). Furthermore, titer levels were much lower for IgM than for IgG AQP4. 
Antibodies of subtype IgM that bind to full length AQP4 were present in 10% of NMO and 
8% of High Risk NMO, but not in any controls (Mader et al., 2010). This is in accordance 
with a study of Jarius et al. detecting IgM antibodies in almost 10% of NMO patients (4 /42) 
but not in any controls (Jarius et al., 2010a). Larger studies are warranted to further analyze 
anti-AQP4 IgG and IgM double positive patients. As anti-AQP4 IgM antibodies are more 
potent to activate the complement cascade, it would be tempting to further investigate the 
clinical parameters of anti-AQP4 IgM positive patients with NMOSD. 
3.7 Cerebrospinal fluid anti-AQP4 antibodies  
Several studies are available concerning anti-AQP4 antibodies in serum samples of patients 
with NMO-spectrum disorders. In contrast, few studies focused on the presence and 
relevance of NMO antibodies in the CSF (Takahashi et al., 2007; Klawiter et al., 2009; Jarius 
et al., 2010b; Dujmovic et al., 2011). Klawiter and colleges reported the presence of CSF anti-
AQP4 antibodies in three seronegative NMO patients (Klawiter et al., 2009), which could not 
be reproduced in other publications. Recently, Jarius et al., detected CSF anti-AQP4 
antibodies in NMO-IgG seropositive patients exceeding anti-AQP4 antibody serum titers ≥ 
1:250, but not in anti-AQP4 antibody negative patients (Jarius et al., 2010b). In cooperation 
with Dujmovic we analyzed the temporal dynamics of CSF anti-AQP4 antibodies in 12 
patients with NMOSD (Dujmovic et al., 2011). Thereby, we could show that longitudinal 
CSF anti-AQP4 IgG correlated with clinical parameters. CSF AQP4-IgG were present in 
patients with high serum titers and correlated with spinal MRI lesion length and CSF 
parameters. Moreover, clinical improvement was associated with a decrease in CSF, but not 
serum, anti-AQP4 IgG titers. Summarizing, CSF AQP4-IgG were associated with clinical 
activity and neuroinflammation (Dujmovic et al., 2011).  
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3.8 Pathogenic role of anti-AQP4 antibodies and T cells in NMO 
In order to address the pathogenic relevance of anti-AQP4 antibodies, several in vitro and in 
vivo studies have been performed so far. Tissue sections showed the distribution of anti-
AQP4 antibodies and products of complement activation surrounding hyalinized blood 
vessels in a rosette-like pattern (Lucchinetti et al., 2002). This deposition of NMO antibodies 
and complement on astrocytes at the glia limitans was accompanied by a loss of the AQP4 
water channel protein (Lennon et al., 2004; Roemer et al., 2007). The cytotoxic effect of anti-
AQP4 antibodies has been demonstrated in several studies so far (Jarius et al., 2008b; Hinson 
et al., 2009; Sabater et al., 2009; Kinoshita et al., 2010). The binding of the anti-AQP4 
antibody led to an activation of the classical complement cascade, resulting in lysis of NMO 
antibody opsonized and AQP4-transfected cells and astrocytes (Jarius et al., 2008b). The 
pathogenic role of anti-AQP4 antibodies has been further supported by several in vivo 
studies using rat and mouse models (Bennett et al., 2009; Bradl et al., 2009; Kinoshita et al., 
2009; Saadoun et al., 2010). Therefore, NMO-IgG antibodies were purified from the plasma 
exchange material of AQP4-IgG positive and negative NMO patients, MS patients and 
control subjects and then injected into animal models (Bradl et al., 2009). Three studies 
demonstrated the formation of NMO-like lesions in Lewis rats following injection of isolated 
human NMO-IgG in the presence of acute T cell mediated CNS inflammation (Bennett et al., 
2009; Bradl et al., 2009; Kinoshita et al., 2009). In contrast, Saadoun proved the formation of 
NMO like lesions after injection of NMO-IgG into mouse brain only in the presence of 
complement, thus by-passing the damage of the blood brain barrier (Saadoun et al., 2010). In 
order to confirm that the NMO like pathology in the animals was due to the anti-AQP4 IgG 
and not based on other antibodies in the plasma exchange material, pre-absorption 
experiments using cells expressing AQP4 were performed (Bradl et al., 2009). This pre-
absorption experiment resulted in a massive decrease of lesion size and was associated with 
less astrocytic damage, confirming the pathogenicity of anti-AQP4 autoantibodies (Bradl et 
al., 2009). As anti-AQP4 antibodies are not sufficient to induce NMO like lesions without 
support of T cells (Bradl et al., 2009) and/or complement (Saadoun et al., 2010), the role of T 
cell mediated immune responses against AQP4 is currently an issue of interest (Nelson et 
al., 2010; Kalluri et al., 2011; Pohl et al., 2011). Supporting evidence for a possible pathogenic 
role of T cells comes from observations showing no formation of NMO like lesions in 
immature rats after injection of anti-AQP4 autoantibodies, although these animals posses a 
leaky blood brain barrier (Bradl et al., 2009). Latest findings by Pohl et al. showed that AQP4 
specific T cells are capable of inducing brain inflammation mainly in astrocytic glia limitans 
and therefore enable an entry of anti-AQP4 autoantibodies (Pohl et al., 2011). As anti-AQP4 
antibodies are detectable more than ten years before disease onset (Nishiyama et al., 2009), 
the time point when these antibodies lead to NMO symptoms remains unresolved. It is 
tempting to speculate that anti-AQP4 antibodies are not harmful if they circulate 
peripherally and as long as they are excluded from the blood brain barrier. Whether a large 
amount of anti-AQP4 autoantibodies is necessary for the patients to develop symptoms 
remains to be investigated. Having access to the blood brain barrier, anti-AQP4 
autoantibodies bind to their target antigen and result in complement activation. This leads 
to vascular hyalinization, necrosis, demyelination and axonal injury (Wingerchuk et al., 
2007). The titer levels seem to have an impact on the disease pathogenesis as antibodies in 
the CSF are only detectable in high titer seropositive patients (Jarius et al., 2010b; Dujmovic 
et al., 2011). Latest findings indicated an influx of systemically produced anti-AQP4 
www.intechopen.com
 
Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights 
 
176 
antibodies through the area postrema (Popescu et al., 2011). This was supported by findings 
of patients suffering from intractable vomiting and nausea as initial symptoms of NMO 
(Popescu et al., 2011).  
4. NMDA-receptor encephalomyelitis 
4.1 Anti-NMDA-receptor encephalitis 
The role of autoantibodies to the ionotropic NMDA (N-methyl-D-aspartate) glutamate 
receptor (NMDA-R; Figure 6) is well established in limbic encephalitis (Graus et al., 2010; 
Vincent et al., 2010; Dalmau et al., 2011).  
 
 
Fig. 6. NMDA-receptor expression on the postsynaptic terminal of neurons.  
These novel autoantibodies were first described by Dalmau et al. in serum samples of young 
women presenting with a subacute-onset encephalopathy often associated with movement 
disorders and an underlying ovarian teratoma (Dalmau et al., 2007; Dalmau et al., 2008). The 
presence of neuronal tissue expressing NMDA-R within the tumour was thought to trigger 
the production of paraneoplastic autoantibodies. However, the origin of the autoantibodies 
remains unresolved, as recent publications reported numerous of non-teratoma associated 
cases. Among some adults, most of these non-paraneoplastic NMDA-R encephalitis cases 
occurred in children (Dale et al., 2009; Florance et al., 2009; Irani et al., 2010). Anti-NMDA-R 
encephalitis is associated with a strong female predominance (female:male ratio is 8:1) 
occurring primarily at a median age of 23 years (Dalmau et al., 2008).  
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The characteristic symptoms of anti-NMDA-R positive patients are of prominent psychiatric 
and behavioral nature, including rapid memory loss, seizures, abnormal movements 
(dyskinesias), hypoventilation and autonomic instability. This disease usually progresses 
from initial neuropsychiatric symptoms into a state of unresponsiveness with catatonic 
features, commonly associated with abnormal movements, and autonomic- and breathing 
instability. Additionally, most patients show prodomal symptoms such as headache, fever, 
nausea, vomiting, diarrhea or upper respiratory-tract symptoms. Brain MRI data show no or 
only minor changes which usually occur transiently despite severity of symptoms. 
Concerning CSF parameters, 60% of patients show OCB and mild lymphocyte pleocytosis 
(Dalmau et al., 2011). Interestingly, intrathecal NMDA-R antibody synthesis was observed 
in a majority of patients and CSF titer levels were more likely to correlate with clinical 
severity, compared to serum titers (Dalmau et al., 2008; Dale et al., 2009; Florance et al., 2009; 
Irani et al., 2010).  
Although the disease can be lethal in some rare cases and despite the severity of the 
symptoms, more than 70% of patients recover after treatment and less than 30% of patients 
show incomplete recovery with memory, cognitive and motor deficits. Treatment options 
include immunotherapy (corticosteroids, intravenous immunoglobulin or plasma exchange) 
and/or tumor removal with the aim to reduce anti-NMDA-R autoantibody levels. Recent 
studies showed that antibodies to the NMDA-R were predominantly of the IgG1 subclass 
and are able to activate complement on NMDA-R expressing human embryonic kidney cells 
(Irani et al., 2010). However, the role of complement activation remains controversial as 
other findings indicated a complement-independent mode of action. Several studies have 
addressed the issue regarding the binding site of the autoantibodies and possible functional 
consequences on the targeted NMDA-R. Dalmau et al. described the NR1 isoform or 
NR1/NR2 heterodimers of the NMDA-R as recognition site of anti-NMDA-R antibodies 
(Dalmau et al., 2011). Providing further insight into the mode of action, in vitro and in vivo 
studies nicely demonstrated that antibodies from patients with anti-NMDA-R encephalitis 
caused a rapid and reversible loss of surface NMDA-R by antibody-mediated capping and 
internalization, resulting in abrogation of NMDA-R-mediated synaptic function (Dalmau et 
al., 2008; Hughes et al., 2010). 
Thus, similar to the role of anti-AQP4 IgG antibodies in NMO, anti-NMDA-R antibodies 
helped to define a new clinical syndrome, anti-NMDA receptor encephalitis (Dalmau et al., 
2011). 
4.2 Anti-NMDA receptor antibodies in neuropsychiatric SLE 
Several reports confirmed the presence of autoantibodies to NMDA-R, particularly the NR2 
isoform, in the majority of patients with neuropsychiatric SLE (DeGiorgio et al., 2001; 
Emmer et al., 2006; Hanly et al., 2006; Kowal et al., 2006; Lapteva et al., 2006; Arinuma et al., 
2008; Fragoso-Loyo et al., 2008). These autoantibodies were not only detected in serum, but 
also in the CSF and brain parenchyma of some SLE patients. Furthermore, CSF titers 
correlate with neuropsychiatric symptoms. In SLE, anti-NMDA-R antibodies were 
demonstrated to bind to a small peptide (DWEYS) present in the extracellular, amino-
terminal domain of NR2A and NR2B subunits (DeGiorgio et al., 2001; Gielen et al., 2009). 
Injection of murine or human monoclonal antibodies against this peptide into the 
hippocampus and cerebral cortex of mice resulted in local loss of neurons and induced 
activation of caspase-3 in cultured human and murine neurons (DeGiorgio et al., 2001; 
Kowal et al., 2006; Gielen et al., 2009). Furthermore, several experimental studies in mice 
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demonstrated a causal relationship between anti-NMDA-R autoantibodies with impairment 
in cognition and behavior (Diamond et al., 2009). A recent study provided evidence of a 
positive modulating effect on receptor function by low concentrations of anti-NMDA-R 
antibodies, resulting in an increase of NMDA-R mediated excitatory postsynaptic potentials. 
However, at high concentrations, these antibodies promote excitotoxicity through enhanced 
mitochondrial permeability transition. These findings might be an explanation for the either 
transient or permanent neuropsychiatric clinical course observed in SLE patients. In 
conclusion, antibodies to the NR2 isoform of NMDA-R could play an important role in the 
pathogenesis of neuropsychiatric lupus. 
Many studies focusing on the detection of antibodies to the NMDA-R NR2A and NR2B 
subunits in SLE have used the ELISA technique. It is now essential that studies regarding 
antibody specificity in patient serum/CSF are confirmed using live cell-based assays 
expressing native NMDA-R or single subunits. 
4.3 Anti-NMDA receptor antibodies in inflammatory demyelinating diseases 
Interestingly, antibodies against NMDA-type glutamate receptors were also detected in both 
serum and CSF of patients with NMOSD (Ishikawa et al., 2007; Kruer et al., 2010). As 
previously described, the discovery of anti-AQP4 IgG antibodies in the serum of patients 
with NMOSD enables an early diagnosis and specific treatment of the disease. Despite the 
high percentage of AQP4-IgG seropositive NMO patients, several studies report on AQP4-
IgG seronegative NMO patients who, however, show no differences in their clinical 
presentation. It might well be that AQP4-IgG seronegative patients represent a distinct 
subgroup of NMO patients, in whom the disease is triggered by other autoantibodies, such 
as antibodies to NMDA-R or yet unknown targets. So far, in literature there is a lack of 
information regarding the presence of anti-NMDA-R antibodies in other CNS demyelinating 
diseases, such as MS. Up to now, one case report speculates on a possible association of the 
rarely occurring epileptic seizures in MS (Catenoix et al., 2010) with anti-NMDA-R antibody 
seropositivity (Johnston et al., 2010). 
5. Conclusion  
The discovery of autoantibodies in different CNS diseases can support an early diagnosis and 
treatment monitoring. Moreover, antibodies can contribute to a better understanding of the 
disease pathogenesis. However, an antibody seronegative result should be handled with care, 
as this can be linked to the assay methodology, study population or to therapeutic 
intervention. In contrast to the high sensitivity and specificity of anti-AQP4 autoantibodies in 
NMO patients, antibodies to MOG are discovered “only” in a subgroup of ADEM patients. 
Hence, there is a lack of a specific biomarker for more than half of patients diagnosed with 
ADEM. Future studies focusing on these seronegative patients might facilitate a 
reclassification of CNS diseases through the identification of novel biomarkers. Finally, 
antibodies to NMDA-R are highly specific for NMDA-receptor encephalitis, whereas their role 
in other neurological diseases has to be confirmed by specific assays. 
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